Loading company analysis...
Johnson & Johnson combines a diversified medicine pipeline and global MedTech portfolio with dependable cash flow, while patent erosion and litigation remain important risks.
Keep researching
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.
Johnson & Johnson is a global healthcare company focused on Innovative Medicine and MedTech. Following the separation of its consumer-health business, the company is more concentrated in prescription medicines, medical devices, surgical technology, orthopaedics, cardiovascular care, and vision products.
Its two operating segments are:
The business model combines patented medicines with procedure-based device revenue. Pharmaceutical products can generate high margins but face clinical, regulatory, and patent risk. MedTech is generally more durable but depends on procedure volumes, hospital budgets, product quality, and surgeon adoption.
Second-quarter sales increased 6.6% to $25.31 billion. Operational growth was 5.6%, while adjusted operational growth was 5.7%.
GAAP net earnings were $5.53 billion, or $2.27 per diluted share. Adjusted net earnings increased 5.7% to $7.08 billion, and adjusted EPS increased 4.7% to $2.90. Adjusted results exclude intangible amortization and special items, so the GAAP and adjusted figures should be considered together.
Innovative Medicine sales increased 7.8% to $16.38 billion. Growth from Darzalex, Carvykti, Tecvayli, Rybrevant and Lazcluze, Tremfya, Spravato, and Caplyta more than offset declining Stelara, Remicade, Imbruvica, and Zytiga sales.
MedTech sales increased 4.5% to $8.93 billion. Growth came from surgery, electrophysiology, Shockwave cardiovascular products, contact lenses, and trauma products.
Management raised full-year guidance to approximately $101.1 billion of reported sales and $11.68 of adjusted EPS at the midpoint. Those targets imply reported sales growth of 7.3% and adjusted EPS growth of 8.2%.
Johnson & Johnson has substantial debt but also reliable cash generation and diversified operations. Acquisitions, licensing, litigation payments, dividends, and drug-development spending compete for capital.
Near $259 per share, Johnson & Johnson's equity value was approximately $633 billion. The stock traded near 30 times trailing earnings and approximately 22 times the midpoint of 2026 adjusted EPS guidance.
The forward adjusted multiple is reasonable for a high-quality healthcare company but not cheap. Continued pipeline execution and enough growth to replace Stelara are required to support the valuation.
Johnson & Johnson's live panel recalculates its EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, resistance, and trend after each completed daily candle. Pharmaceutical stocks can gap on clinical, regulatory, patent, and legal news, so event risk should be considered before trading.
The automated panel estimates fair value gaps, order blocks, breaks of structure, changes of character, and liquidity zones. Large trial, earnings, and litigation gaps can remain important reference areas. Confirm zones with price action and volume.
The main checkpoints are Stelara erosion, oncology growth, pipeline data, MedTech procedure growth, adjusted margin, free cash flow, and legal developments.
Final view: Johnson & Johnson earns a moderately bullish 78 because its diversified medicines, MedTech portfolio, pipeline, cash flow, and raised guidance support durable growth. Patent erosion, litigation, pricing pressure, debt, and clinical execution prevent a higher rating.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.
Eli Lilly is delivering exceptional growth through Mounjaro and Zepbound while expanding its cardiometabolic pipeline and manufacturing capacity.
AbbVie has successfully shifted growth toward Skyrizi, Rinvoq, and neuroscience, while acquisitions, high debt, and product concentration remain central risks.
UnitedHealth is showing a meaningful earnings and medical-cost recovery across UnitedHealthcare and Optum, but membership contraction, regulation, and investigations remain central risks.
Recalculated automatically from daily market data. Values are cached for one hour and use the latest completed candle. Smart money zones are algorithmic estimates and should be confirmed on the chart.
Automatically refreshed from Finnhub. Open each source to evaluate how the development affects the thesis.
The pharmaceutical icon's dividend yield has been pared back by the stock's recent rally, driven by a new growth initiative.
Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.
Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company’s talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to other large...
Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.
